02375oam 2200625 450 991071666640332120220408141333.0(CKB)5470000002523500(OCoLC)1259368245(EXLCZ)99547000000252350020210707d2018 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierExamining FDA's generic drug and biosimilar user fee programs hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, March 2, 2017Washington :U.S. Government Publishing Office,2018.1 online resource (v, 136 pages) illustrations"Serial No. 115-10."Includes bibliographical references.Examining FDA's generic drug and biosimilar user fee programs User chargesLaw and legislationfastPrescription pricingLaw and legislationfastGeneric drugsPricesfastDrugsLaw and legislationfastGeneric drugsPricesUnited StatesPrescription pricingLaw and legislationUnited StatesUser chargesLaw and legislationUnited StatesDrug accessibilityGovernment policyUnited StatesDrugsLaw and legislationUnited StatesUnited StatesfastRules.fastLegislative hearings.fastLegislative hearings.lcgftUser chargesLaw and legislation.Prescription pricingLaw and legislation.Generic drugsPrices.DrugsLaw and legislation.Generic drugsPricesPrescription pricingLaw and legislationUser chargesLaw and legislationDrug accessibilityGovernment policyDrugsLaw and legislationGPOGPOGPOOCLCOOCLCQOCLGPOBOOK9910716666403321Examining FDA's generic drug and biosimilar user fee programs3463660UNINA